A study sponsored by Cyberonics Inc., Houston, TX, shows that patients with treatment-resistant depression are very costly to the healthcare system due to extremely high use of both depression-related and general medical services. The study analyzed medical and prescription claims data from the 1995-1998 MEDSTAT MarketScan® Databases to evaluate healthcare utilization and costs of patients with treatment-resistant depression.
A study sponsored by Cyberonics Inc., Houston, TX, shows that patients with treatment-resistant depression are very costly to the healthcare system due to extremely high use of both depression-related and general medical services. The study analyzed medical and prescription claims data from the 1995-1998 MEDSTAT MarketScan® Databases to evaluate healthcare utilization and costs of patients with treatment-resistant depression.
The study found that treatment-resistant depression was associated with higher inpatient, outpatient and total healthcare costs. Specifically, average total annual healthcare costs for patients with low-to-moderate treatment-resistant depression were $9,191, compared with $41,475 for those with severe treatment-resistant depression. Treatment-resistant patients were twice as likely to be hospitalized, and they had 15% more outpatient visits than the non-treatment-resistant depressed group. Treatment resistance was associated with two to three times more psychotropic medication use in addition to antidepressant medications. Treatment-resistant patients were also more likely to be diagnosed with bipolar disorders, co-morbid anxiety and substance-related disorders.
Said Ernst Berndt of the Massachusetts Institute of Technology: "These results provide strong evidence that treatment-resistant depression generates huge costs for the healthcare system, and underscore the need to find effective, tolerable, long-term treatment options for this patient population." PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.